Unknown

Dataset Information

0

Integrative computational approach identifies drug targets in CD4+ T-cell-mediated immune disorders.


ABSTRACT: CD4+ T cells provide adaptive immunity against pathogens and abnormal cells, and they are also associated with various immune-related diseases. CD4+ T cells' metabolism is dysregulated in these pathologies and represents an opportunity for drug discovery and development. Genome-scale metabolic modeling offers an opportunity to accelerate drug discovery by providing high-quality information about possible target space in the context of a modeled disease. Here, we develop genome-scale models of naïve, Th1, Th2, and Th17 CD4+ T-cell subtypes to map metabolic perturbations in rheumatoid arthritis, multiple sclerosis, and primary biliary cholangitis. We subjected these models to in silico simulations for drug response analysis of existing FDA-approved drugs and compounds. Integration of disease-specific differentially expressed genes with altered reactions in response to metabolic perturbations identified 68 drug targets for the three autoimmune diseases. In vitro experimental validation, together with literature-based evidence, showed that modulation of fifty percent of identified drug targets suppressed CD4+ T cells, further increasing their potential impact as therapeutic interventions. Our approach can be generalized in the context of other diseases, and the metabolic models can be further used to dissect CD4+ T-cell metabolism.

SUBMITTER: Puniya BL 

PROVIDER: S-EPMC7822845 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Integrative computational approach identifies drug targets in CD4<sup>+</sup> T-cell-mediated immune disorders.

Puniya Bhanwar Lal BL   Amin Rada R   Lichter Bailee B   Moore Robert R   Ciurej Alex A   Bennett Sydney J SJ   Shah Ab Rauf AR   Barberis Matteo M   Helikar Tomáš T  

NPJ systems biology and applications 20210122 1


CD4<sup>+</sup> T cells provide adaptive immunity against pathogens and abnormal cells, and they are also associated with various immune-related diseases. CD4<sup>+</sup> T cells' metabolism is dysregulated in these pathologies and represents an opportunity for drug discovery and development. Genome-scale metabolic modeling offers an opportunity to accelerate drug discovery by providing high-quality information about possible target space in the context of a modeled disease. Here, we develop gen  ...[more]

Similar Datasets

| S-EPMC8804607 | biostudies-literature
| S-EPMC9397618 | biostudies-literature
| S-EPMC5265847 | biostudies-other
| S-EPMC3362030 | biostudies-literature
2023-03-11 | PXD027329 | Pride
| S-EPMC9483418 | biostudies-literature
| S-EPMC6035197 | biostudies-literature
| S-EPMC6050338 | biostudies-literature
| S-EPMC4768263 | biostudies-literature
| S-EPMC9715589 | biostudies-literature